Abstract
Without any realistic prospect of comprehensive global vaccine coverage and lasting immunity, control of pandemics such as COVID-19 will require implementation of large scale, rapid identification and isolation of infectious individuals to limit further transmission. Here, we describe an automated, high-throughput testing instrument, designed for population-scale testing for SARS-CoV-2 RNA within 25 minutes from inactivated saliva to result, and capable of reporting 3,840 results per hour. This integrated screening platform incorporates continuous flow loading of samples at random intervals to cost-effectively adjust for fluctuations in testing demand. Protecting vulnerable populations during global pandemics requires rapid and sensitive infection surveillance of asymptomatic carriers. This “Sentinel” surveillance system offers a feasible and scalable approach to complement vaccination, to curb the spread of COVID-19 variants and future pandemics to save lives.
One-Sentence Summary Development of an automated continuous flow, random access SARS-CoV-2 screening platform with sufficient speed, throughput, and sensitivity to enable pandemic-scale surveillance and isolation of infectious individuals.
Competing Interest Statement
PW and PO are founders of Avicena Systems, SK is founder of the Prion.
Funding Statement
Development of the Avicena Sentinel Instrument was supported by grants from the Department of Health, Western Australia, Department of Premier and Cabinet of Western Australia, Western Australian Department of Jobs, Tourism, Science and Industry, and a federal grant Modern Manufacturing Initiative grant from the Department of Industry, Science, Energy and Resources, Australian Government. SK was supported by the Perron Institute for Neurological and Translational Science, Perth, WA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sir Charles Gairdner and Osborne Park Health Care Group Human Research Ethics Committee gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data and materials availability
All data are available in the main text or the supplementary materials.